Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

NCT07540832 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: WGI-0301
DRUG: WGI-0301
DRUG: Lenvatinb

Sponsor

Zhejiang Haichang Biotech Co., Ltd.